0
Skip to Content
Optimo Capital
Optimo Capital
About
Pre-IPOs
Research Services
Research Client List
Research Library
Daily Analysis
Contact & Sign Up
Optimo Capital
Optimo Capital
About
Pre-IPOs
Research Services
Research Client List
Research Library
Daily Analysis
Contact & Sign Up
About
Pre-IPOs
Folder: Equity Research
Back
Research Services
Research Client List
Research Library
Daily Analysis
Contact & Sign Up
Touchstar - transformation on track, but market wary as recovery waits for 2027
Ryan McCallum 02/09/2026 Ryan McCallum 02/09/2026

Touchstar - transformation on track, but market wary as recovery waits for 2027

The connected technology solutions firm remains on track for a return to profitability in 2027. Plus, the CEO has been increasing his shareholding in recent months.

Read More
MedPal AI - GLP-1s move from weight loss to heart health, widening New Health's market
Ryan McCallum 01/09/2026 Ryan McCallum 01/09/2026

MedPal AI - GLP-1s move from weight loss to heart health, widening New Health's market

Each new proven benefit is bringing a new population of patients into Mounjaro’s addressable market.

Read More
Halfords - shares surge as profit guidance lands a maximum 24% above consensus
Ryan McCallum 27/08/2026 Ryan McCallum 27/08/2026

Halfords - shares surge as profit guidance lands a maximum 24% above consensus

Underlying profit before tax for FY2027 is now expected to be between £55 million - £65 million.

Read More
Nexteq - Densitron drives into automotive with a new EV display win
Ryan McCallum 26/08/2026 Ryan McCallum 26/08/2026

Nexteq - Densitron drives into automotive with a new EV display win

An important contract win for the firm’s human-machine interfaces business.

Read More
Volex - on course for FTSE 250 after profit upgrade and 28% revenue growth
Ryan McCallum 25/08/2026 Ryan McCallum 25/08/2026

Volex - on course for FTSE 250 after profit upgrade and 28% revenue growth

Volex expects its FY2027 underlying operating profit to be ahead of current market expectations..

Read More
EDX Medical - £2.7m raised at a premium, but the warrants tell the story
Ryan McCallum 24/08/2026 Ryan McCallum 24/08/2026

EDX Medical - £2.7m raised at a premium, but the warrants tell the story

The money raised will support the expansion of the company's new employee health screening service.

Read More
Tekcapital - Guident and Lucyd updates as market discounts the Vesari-driven NAV
Ryan McCallum 21/08/2026 Ryan McCallum 21/08/2026

Tekcapital - Guident and Lucyd updates as market discounts the Vesari-driven NAV

A double set of news from the UK intellectual property investment group has sent the shares up by a modest 3%.

Read More
Crusoe - AI infrastructure group weighs IPO amid $30bn round talks
Ryan McCallum 20/08/2026 Ryan McCallum 20/08/2026

Crusoe - AI infrastructure group weighs IPO amid $30bn round talks

Crusoe completed an oversubscribed Series E funding round in October 2025 at a valuation “above $10 billion”.

Read More
Canuc Resources - launches major airborne gravity survey targeting deep discovery potential at East Sudbury
Ryan McCallum 19/08/2026 Ryan McCallum 19/08/2026

Canuc Resources - launches major airborne gravity survey targeting deep discovery potential at East Sudbury

The comprehensive survey program will cover close to 2,000 line-kilometres giving Canuc one of the most detailed subsurface pictures ever compiled on the project.

Read More
Huddled Group - shares up 21% on live-commerce software launch and JV
Ryan McCallum 18/08/2026 Ryan McCallum 18/08/2026

Huddled Group - shares up 21% on live-commerce software launch and JV

Huddled has developed software intended to address a key constraint in scaling live commerce.

Read More
Nicola Mining - another partner signed, solidifying the Merritt Mill’s place as BC's shared processing hub
Ryan McCallum 17/08/2026 Ryan McCallum 17/08/2026

Nicola Mining - another partner signed, solidifying the Merritt Mill’s place as BC's shared processing hub

The Agreement will focus exclusively on precious-metal opportunities, with profits being shared equally between Nicola and Red Eye.

Read More
MedPal AI - second GLP-1 pill approval in two months feeds New Health
Ryan McCallum 13/08/2026 Ryan McCallum 13/08/2026

MedPal AI - second GLP-1 pill approval in two months feeds New Health

This is an area upon which MedPal has been focussed recently, launching its dedicated weight-loss website New Health.

Read More
Shoe Zone - £3.47m buyback targets nearly half a thin free float
Ryan McCallum 12/08/2026 Ryan McCallum 12/08/2026

Shoe Zone - £3.47m buyback targets nearly half a thin free float

Nearly half the company’s cash will be used to buy back its shares.

Read More
Canuc Resources - shares now Depository Trust Company (DTC) eligible
Ryan McCallum 11/08/2026 Ryan McCallum 11/08/2026

Canuc Resources - shares now Depository Trust Company (DTC) eligible

Canuc believes this will make its shares more accessible to U.S. investors, broadening the shareholder base and improving liquidity.

Read More
Nicola Mining - makes an additional strategic investment in Blue Lagoon Resources
Ryan McCallum 11/08/2026 Ryan McCallum 11/08/2026

Nicola Mining - makes an additional strategic investment in Blue Lagoon Resources

The funds will be used to ramp-up mining activities at the Dome Mountain Gold Mine.

Read More
Thruvision - shares surge on largest ever contract win in Asia
Ryan McCallum 10/08/2026 Ryan McCallum 10/08/2026

Thruvision - shares surge on largest ever contract win in Asia

The deployment is expected to generate more than £3 million of revenue for the company.

Read More
Sanderson Design Group - a “royally” good first half after North America drives sales
Ryan McCallum 07/08/2026 Ryan McCallum 07/08/2026

Sanderson Design Group - a “royally” good first half after North America drives sales

Full-year trading is expected to be in line with market expectations which are for adjusted underlying pre-tax profits of £6.5 million.

Read More
Corero - bounces back with 42% growth and Tier-1 contract win
Ryan McCallum 06/08/2026 Ryan McCallum 06/08/2026

Corero - bounces back with 42% growth and Tier-1 contract win

Corero shares up by 12% to 9.25p on a positive first half trading statement.

Read More
B90 Holdings - H1 revenue ahead of expectations as AI investment ramps up
Ryan McCallum 05/08/2026 Ryan McCallum 05/08/2026

B90 Holdings - H1 revenue ahead of expectations as AI investment ramps up

Trading during the first half is said to have remained strong, with revenue for the period expected to be ahead of management expectations.

Read More
MedPal AI - zero to £8.6m in nine months after a record July
Ryan McCallum 04/08/2026 Ryan McCallum 04/08/2026

MedPal AI - zero to £8.6m in nine months after a record July

MedPal’s annualised recurring revenue run rate stands at £8.6 million based on the July figures. All revenues are predictable, quality, recurring streams of income.

Read More
Older Posts

ENQUIRY

Please register your interest below and a member of our team will be in contact.

Thank you!

CONTACT

Email us at: info@optimocapital.co.uk

Call us on 07711 828 771

Follow us on social media

LEGAL

Privacy Policy

Disclosures, disclaimers & risk warnings

This website acts as a portal for both Optimo Capital Limited and Optimo Research Ltd, two separate companies registered with Companies House in the UK which share a majority shareholder.

Optimo Capital Limited is a private limited company (Companies House number 13017605) with its registered office at 124 City Road, London, EC1V 2NX. Optimo Capital Limited undertakes activities which are not regulated by the Financial Conduct Authority, namely acting as an introducer between companies and potential providers of capital.

Optimo Research Ltd is a private limited company (Companies House number 06427125) with its registered office at 124 City Road, London, EC1V 2NX. Optimo Research Ltd offers professional equity research services to growth companies and the companies covered pay a fee in order for this research to be made available. Optimo Research Ltd is authorised & regulated by the Financial Conduct Authority. FRN No. 768993.

Nothing in our research reports should be construed as an offer or the solicitation of an offer to buy or sell securities by us and, as we have no knowledge of your individual situation and circumstances, you should not make any investment decision without consulting a fully qualified financial adviser. Research notes do not constitute advice and your capital is at risk by investing in the financial instruments issued by the companies discussed. For full disclosures, disclaimers and risk warnings click here.